Ipratropium bromide does not contain any steroids. It belongs to an entirely different class of medication called anticholinergics (sometimes called antimuscarinics), which work by blocking a specific nerve signal in the airways rather than by reducing inflammation the way corticosteroids do. The confusion is understandable, since ipratropium is delivered through an inhaler or nebulizer just like many steroid-based medications, and it is frequently prescribed alongside corticosteroids for the same lung conditions. But the drug itself is steroid-free, and its mechanism, benefits, and side-effect profile are distinct from those of any corticosteroid.
What Ipratropium Bromide Actually Is
Ipratropium bromide is a synthetic derivative of atropine, a naturally occurring compound found in plants like belladonna. It works by blocking acetylcholine, a chemical messenger that tells the smooth muscles around your airways to tighten. When those signals are blocked, the muscles relax and the airways open up. This is a fundamentally different approach from corticosteroids, which reduce airway inflammation, swelling, and mucus production over time. Ipratropium does not suppress inflammation at all; it simply relaxes the muscles mechanically.
Compared to the fast-acting bronchodilators most people are familiar with (like albuterol), ipratropium has a slower onset but tends to last longer. Studies have shown that ipratropium reaches its peak effect more gradually than beta-agonist bronchodilators, though the total bronchodilation over time is comparable.1The American Journal of Medicine. Ipratropium bromide in asthma: A review of the literature That slower-but-steadier profile is part of why it is often paired with a faster-acting drug rather than used alone for quick relief.
Why People Think It Might Be a Steroid
Several things feed this misconception. First, ipratropium is delivered in the same way as inhaled corticosteroids: through metered-dose inhalers, soft-mist inhalers, or nebulizer solutions. If you have been told you are on an “inhaler,” it is natural to assume the medication inside is a steroid, since inhaled corticosteroids are among the most commonly prescribed inhaler drugs for asthma and COPD.
Second, ipratropium is very often prescribed in combination products that do include other drugs. The well-known combination of ipratropium with albuterol (sold as Combivent, among other names) pairs two non-steroidal bronchodilators together. But in broader treatment plans for COPD, patients may be on an anticholinergic plus an inhaled corticosteroid plus a long-acting beta-agonist. When you are juggling multiple inhalers, it is easy to lose track of which one contains what. The ipratropium inhaler itself, however, contains no steroid component.
Third, some people develop a broad anxiety about any inhaled medication being a steroid, a phenomenon researchers have documented as “corticophobia.” Studies of asthma patients have found that a significant proportion worry about the side effects of inhaled corticosteroids and may resist using them or confuse other inhaled drugs with steroids. That fear can bleed over onto non-steroidal inhalers like ipratropium, even though they carry none of the steroid-related risks people are concerned about.
How Ipratropium Differs from Inhaled Corticosteroids in Practice
The clinical distinction between ipratropium and an inhaled corticosteroid is not just academic; it changes what you can expect from the medication. A landmark trial published in the New England Journal of Medicine compared patients with obstructive airway disease who were randomized to receive either an inhaled corticosteroid or ipratropium. The corticosteroid group saw their lung function improve by about 10% of predicted value within three months and maintain that improvement, while the ipratropium group showed no comparable gain in lung function over time. Patients on ipratropium also withdrew from the study at much higher rates due to worsening pulmonary symptoms.2New England Journal of Medicine. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease
This does not mean ipratropium is ineffective. It means the two drugs do different jobs. Corticosteroids address the underlying inflammation that drives conditions like asthma and COPD. Ipratropium opens the airways in the short term by relaxing muscle tone. In many treatment plans, both are needed, and neither can fully replace the other. If your doctor has you on ipratropium, it is filling a bronchodilator role, not an anti-inflammatory one. Stopping a prescribed corticosteroid because you believe ipratropium “covers the same ground” would be a mistake.
Where Ipratropium Is Used
Ipratropium has been a mainstay in the treatment of COPD for decades. It has a relatively short duration of action, typically four to eight hours, and has been used both for daily maintenance and for acute flare-ups of airway obstruction, either alone or combined with a short-acting beta-agonist like albuterol.3PubMed. Anticholinergic agents in asthma and COPD In recent years, longer-acting anticholinergics like tiotropium have taken over much of the daily maintenance role, but ipratropium remains widely used in emergency and acute-care settings.
In asthma, ipratropium is not typically a first-line controller medication, but it plays an important supporting role during acute attacks. A meta-analysis of adults with acute asthma found that adding ipratropium to standard beta-agonist therapy produced a meaningful improvement in lung function and, more strikingly, reduced the odds of hospital admission by roughly a third.4PubMed. A meta-analysis of the effects of ipratropium bromide in adults with acute asthma That reduction in hospitalizations is especially pronounced in patients who arrive with severe obstruction. A pooled analysis of three trials confirmed that combination therapy with ipratropium and a beta-agonist reduced the risk of needing additional treatment and lowered the chance of hospitalization compared to a beta-agonist alone.5PubMed. The effect of adding ipratropium bromide to salbutamol in the treatment of acute asthma: a pooled analysis of three trials
Beyond the lungs, ipratropium also comes in a nasal spray formulation. The 0.03% nasal spray is approved specifically for treating a runny nose (rhinorrhea) in both allergic and non-allergic perennial rhinitis.6PubMed Central. Ipratropium bromide nasal spray 0.03% and beclomethasone nasal spray alone and in combination for the treatment of rhinorrhea in perennial rhinitis The nasal version works the same way as the inhaled version: it blocks acetylcholine signals, this time in the nasal glands, to reduce excess mucus production. It does not treat congestion or sneezing, just the dripping. This is another context where patients may wonder whether the spray is “a steroid” because nasal corticosteroid sprays (like fluticasone) are so common. Again, the ipratropium nasal spray is steroid-free.
Side Effects You Will and Won’t See
Because ipratropium is not a steroid, you will not experience steroid-specific side effects like oral thrush (candidiasis), thinning skin, bone density loss, or adrenal suppression. Those concerns are associated with corticosteroids, particularly at higher doses or with long-term use. Ipratropium’s side-effect profile is its own, and for most people it is quite mild. Clinical trials have found that side effects were mostly minor and that none of the reported problems were attributed to the ipratropium itself when it was added to an existing bronchodilator regimen.7Chest. The Addition of An Aerosol Anticholinergic to An Oral Beta Agonist Plus Theophylline in Asthma and Bronchitis
That said, ipratropium does carry anticholinergic side effects that are worth knowing about. Because it blocks acetylcholine, it can cause dry mouth, a bitter taste, and drying of secretions. These are usually tolerable and are the most commonly reported complaints. The drug’s anticholinergic properties can also, in rarer cases, lead to urinary retention, constipation, or increased eye pressure (intraocular pressure), which is a concern for people with narrow-angle glaucoma.8Current Therapeutic Research. The effect of ipratropium bromide on intraocular pressure in patients with chronic obstructive pulmonary disease: an open-label study
The urinary retention issue deserves special mention because it disproportionately affects a specific group. Case reports and reviews have consistently found that urinary retention from ipratropium occurs almost exclusively in older men who already have an enlarged prostate. In these patients, the anticholinergic effect can tip the balance and cause difficulty urinating, sometimes severe enough to require medical intervention. The problem resolves once the drug is stopped.9PubMed. Urinary retention associated with ipratropium bromide Higher doses delivered through nebulizers seem to carry more risk than standard inhaler doses.10Postgraduate Medical Journal. Bladder outflow obstruction induced by ipratropium bromide The official prescribing information for combination products containing ipratropium notes urinary retention as a post-marketing adverse event and advises caution in patients with bladder-neck obstruction or an enlarged prostate.11PubMed Central. Ipratropium Bromide/Salbutamol-Induced Acute Urinary Retention as a Result of Medication Error: A Case Report and Review of Cases in the Literature
When Ipratropium and Steroids Are Prescribed Together
For many people with moderate-to-severe COPD or poorly controlled asthma, the treatment plan involves multiple drug classes working at the same time. A common approach in COPD is “triple therapy,” which combines a long-acting anticholinergic (often tiotropium, the longer-acting cousin of ipratropium), a long-acting beta-agonist, and an inhaled corticosteroid, all in a single inhaler or as separate devices. In acute-care settings, ipratropium itself may be nebulized alongside a beta-agonist while the patient is also on an inhaled or systemic corticosteroid for inflammation control.
The reason these drugs are stacked is that each one addresses a different piece of the problem. The anticholinergic relaxes airway smooth muscle through one pathway. The beta-agonist relaxes the same muscle through a different pathway, giving an additive effect. The corticosteroid dampens the inflammatory process that narrows the airways in the first place. None of these replaces the others. If you are told to use ipratropium and separately told to use a corticosteroid inhaler, both prescriptions are intentional and both are needed. The ipratropium is not “already covering” the steroid’s job.
Telling Your Inhalers Apart
If you have multiple inhalers and are unsure which contains what, the simplest approach is to check the generic drug name on the label or patient information sheet. Inhaled corticosteroids will list names like fluticasone, budesonide, beclomethasone, mometasone, or ciclesonide. Anticholinergics will list ipratropium, tiotropium, umeclidinium, aclidinium, or glycopyrrolate. Beta-agonists will list albuterol (salbutamol), formoterol, salmeterol, vilanterol, or similar. Combination inhalers list two or three of these together.
Some common combinations to be aware of:
- Combivent Respimat: ipratropium plus albuterol. No steroid.
- DuoNeb: ipratropium plus albuterol in nebulizer solution. No steroid.
- Advair / Symbicort / Breo: a corticosteroid plus a long-acting beta-agonist. No anticholinergic.
- Trelegy / Breztri: a corticosteroid plus a long-acting beta-agonist plus a long-acting anticholinergic. These do contain a steroid, along with two other classes.
If you see ipratropium on the label, the device does not contain a steroid. If you see one of the corticosteroid names alongside it in a combination product, then that specific combination product does include a steroid, but it is the other ingredient, not the ipratropium, providing it.
Ipratropium’s Slower Onset and What That Means for You
One practical detail that trips people up is how quickly ipratropium works compared to a rescue inhaler. Albuterol, the most common rescue bronchodilator, typically starts opening airways within minutes. Ipratropium takes longer to reach full effect, though its bronchodilation tends to persist longer once it kicks in.12The American Journal of Medicine. Use of ipratropium bromide in asthma: Results of a multi-clinic study The total amount of airway opening over the course of several hours is similar between the two, but the timing is different. This is why, in emergency rooms, ipratropium is almost always given alongside a fast-acting beta-agonist rather than instead of one. The beta-agonist provides rapid relief while the ipratropium adds a slower, sustained layer of bronchodilation on top.
For daily COPD management, this timing profile matters less, since you are dosing on a schedule rather than responding to an emergency. But if you have been given ipratropium as part of an acute treatment, do not be discouraged if you do not feel immediate improvement the way you would with albuterol. The drug’s full benefit takes a bit longer to build, and the two medications complement each other in that regard.
The Eye Spray Problem
One side effect worth knowing about, especially for nebulizer users, involves the eyes. When ipratropium is delivered through a nebulizer, the mist can drift onto the face and contact the eyes. In susceptible individuals, particularly those with narrow-angle glaucoma, this can trigger a spike in intraocular pressure or pupil dilation. The risk is largely avoidable by using a mouthpiece rather than a face mask during nebulization, or by ensuring the mask fits snugly enough that the mist does not escape around the nose and eyes. With metered-dose inhalers or the Respimat device, the issue is essentially nonexistent because the medication is directed into the mouth.
This eye-related risk is another distinctly anticholinergic concern, not a steroid concern. Inhaled corticosteroids carry their own long-term eye risks (cataracts and, less commonly, glaucoma with prolonged high-dose use), but those develop over months or years. Ipratropium’s eye effect is immediate and local, caused by direct contact of the anticholinergic mist with the eye surface. The two risks are unrelated in mechanism and timeline, which further underscores that these are fundamentally different drug classes doing different things in your body.